Document is current
Any future updates will be listed below
-
Authors
Lin, Zhenyu
Zhang, Peng
Cai, Ming
Li, Gang
Liu, Tao
Cai, Kailin
Wang, Jing
Liu, Junli
Liu, Hongli
Zhang, Weikang
Gao, Jinbo
Wu, Chuanqing
Wang, Linfang
Wang, Zheng
Hou, Zhiguo
Kou, Hongyi
Tao, Kaixiong
Zhang, Tao
-
Funding
Funding for this research was provided by:
Wuhan Union Hospital Innovation Research (No. 2021xhyn063)
Chinese Society of Clinical Oncology (CSCO)-Tongshu Oncology Research Fund (No. Y-tongshu2021/qn-0205)
National Natural Science Foundation of China (No.82373050)
Chinese Society of Clinical Oncology (CSCO)-Xinda Oncology Immunotherapy Research Fund (No. Y-XD202002-0168)
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 24 April 2025
First Online: 9 May 2025
Declarations
:
: This trial was done in accordance with the Declaration of Helsinki and Good Clinical Practices and the study protocol was approved by the Ethics Committee of Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology (No. S1172). All enrolled patients provided written informed consent.
: Not applicable.
: ZH and HK are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. All other authors declare that they have no competing interests.
